Skip to main content

A phase 2 study of AFM13, a bispecific cell engager targeting CD30 and CD16A, in combination with modified natural killer cells in patients with CD30-positive lymphoma


TAP Partner

Project Term: August 26, 2013 - June 30, 2020

In August 2013, LLS began its first European partnership with Affimed that supported two clinical trials for Hodgkin lymphoma (HL) patients. Expanding upon the initial work supported by LLS TAP, Affimed is currently enrolling "Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas."

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system using the proprietary ROCK® platform to enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors.

AFM13 is bispecific tetravalent engager targeting CD30 on tumor cells and CD16A on NK cells and macrophages. AFM13 in combination with modified natural killer cells is currently in a Phase 2 clinical trial in relapsed or refractory CD30-positive lymphoma (NCT04074746).

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects